Acute Rejection Features in Dual Kidney Transplant Recipients from Elderly Donors: Comparison of Calcineurin Inhibitor-Based and Calcineurin Inhibitor-Free Immunosuppressive Protocols

Abstract

Features of acute rejection in dual kidney transplant have not been studied. The aim of this study is to compare acute rejections in dual kidney transplant recipients from elderly donors on different immunosuppressive protocols. Sixty-nine patients were evaluated: 28 received calcineurin inhibitor-based (group 1) and 41 received calcineurin inhibitor-free immunosuppression (group 2). Histology of all donor kidneys was evaluated before implantation. All rejections showed tubulitis in both groups, and were classified as T cell-mediated acute rejections. Incidence and Banff grade of rejections in the two groups were not significantly different. Late rejections however, were observed in group 1 (P < 0.01) whereas steroid-resistant rejections occurred in group 2 (P < 0.03). C4d deposition was only observed in group 2. Occurrence of acute rejection was significantly associated with graft loss due to interstitial fibrosis/tubular atrophy in both groups. In group 1 mean serum creatinine levels of patients with rejections at six months and one year were higher than those of patients without rejections (P < 0.03 and P < 0.009, respectively). In group 2 they were higher at six months (P < 0.01) but not at one year. In addition, graft loss due to interstitial fibrosis/tubular atrophy occurred in 3/28 patients in group 1 (10.7%, OR= 1.95, 95%CI 1.02–3.71), and in 1/41 patients in group 2 (2.4%, OR= 0.41, 95%CI 0.07–2.24). Taken together these results suggest better renal function in patients on calcineurin inhibitor-free immunosuppression. In conclusion, acute rejections were detrimental irrespective of the type of immunosuppression, but different features were observed with each therapy. A tailored approach should be advantageous for prevention and treatment of acute rejections.

Keywords

dual kidney transplant acute rejection immunosuppressive therapy

References

Nankivell

Borrows

Fung

O'Connell

Allen

Chapman

. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326–33.

Solez

Colvin

Racusen

. 2007 Banff 07 classification of renal allograft pathology. Updates and future directions. Am J Transplant 2008; 8:1–8.

Cornell

Colvin

. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2005; 14:229–34.

Matas

. Chronic rejection in renal transplant recipients — risk factors and correlates. Clin Transplant 1994; 8:332–5.

Hariharan

Johnson

Bresnahan

Taranto

McIntosh

Stablein

. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:1837–8.

Joosten

Sijpkens

van Kooten

Paul

. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68:1–13.

Racusen

Solez

Colvin

. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713–23.

Manuiyyedi

Crespo

Collins

. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779–87.

Regele

Exner

Watschinger

. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16:2058–66.

10.

Bohmig

Exner

Habicht

. Capillary C4d deposition in kidney allograft: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13:1091–99.

11.

Racusen

Colvin

Solez

. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708–14.

12.

Herzenberg

Gill

Djurdjev

Magil

. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234–41.

13.

Jianghua

Wenqing

Huiping

Juan

Jiandoyong

Qiang

. C4d as a significant predictor for humoral rejection in renal allografts. Clin Transplant 2005; 19:785–91.

14.

Metzger

Delmonico

Feng

Port

Wynn

Merion

. Expanded criteria donor for kidney transplantation. Am J Transplant 2003; 3:114–25.

15.

Chavalithdhramrong

Gill

Takemoto

Madhira

Cho

Shah

Bunnapradist

. Patient and graft outcomes from deceased kidney donors age 70 years and older: An analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing Database. Transplantation 2008; 85: 1573–79.

16.

Mehrabi

Fonouni

Kashfi

. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006; 20:30–43.

17.

Reutzel-Selke

Jurish

Denecke

. Donor age intensifies the early immune response after transplantation. Kidney Int 2007; 71:629–36.

18.

Sanchez-Fructuoso

Naranjo Garcia

Calvo Romero

Ridao

Naranjo Gomez

Conesa

Barrientos

. Effect of the brain-death process on acute rejection in renal transplantation. Transplant Proc 2007; 39:2214–16.

19.

Remuzzi

Grinyo

Ruggenenti

Beatini

Cole

Milford

Brenner

. Early experience with dual kidney transplantation in adults using expanded criteria donors. J Am Soc Nephrol 1999; 10:2591–98.

20.

DiJoseph

Sharma

Chang

. The effect of rapamycin on kidney function in the Sprague-Dwaley rat. Transplantation 1992; 53:507–13.

21.

Golbaekdal

Nielsen

Djurhuus

Pedersen

. Effects of rapamycin on renal hemodynamics, water and sodium excretation, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation 1994; 58: 1153–57.

22.

Kahan

Julian

Pescovitz

Vanrenterghem

Neylan

. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68:1526–32.

23.

Groth CG Backman L Morales JM et al. for the Sirolimus European Renal Transplant Study Group. Sirolimus (Rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67:1036–42.

24.

Kreis H Cisterne JM Land W et al. for the Sirolimus European Renal Transplant Study Group. Transplantation 2000; 69:1252–60.

25.

Johnson

RWG

Kreis

Oberbauer

Brattstrom

Claesson

Eris

. Sirolimus allows early cyclosporine withrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777–86.

26.

van den Akker

Hené

Hoitsma

. Inferior results with basic immunosuppression with sirolimus in kidney tranplantation. Neth J Med 2007; 65:23–28.

27.

Humar

Kerr

Gilligham

Matas

. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68:1200–03.

28.

Pallardo Mateu

Sancho Calabuig

Capdevila Plaza

Franco Esteve

. Acute rejection and late renal transplant failure: risk factor and prognosis. Nephrol Dial Transplant 2004; 19:iii38–iii42.

29.

Knechtle

Pirsch

Fechner

. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3:722–30.

30.

Hazzan

Buob

Labalette

Glowacki

Hoffman

Copin

Noel

. Assessment of the risk of chronic allografts dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006; 82:657–62.